Immunovant
✦ Quant Ownership Signal how this is computed
- The number of reporting institutions increased by 5 in the most recent period (2026/Q3).
- Total institutional ownership rose 4.4 percentage points.
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 113.31% +4.38pp
- Institutions
- 274 +5
- As of
- 2026/Q3 vs. prior period
Holder types
Top holders as of 2025-12-12
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 17 buys · 33 sells
| Name | Role | Stake |
|---|---|---|
| Roivant Sciences Ltd. | -- | 54.76% |
| Peter Salzmann | Former Chief Executive Officer | 0.30% |
| William Macias | Former CMO Emeritus | 0.10% |
| Eva Barnett | Former Chief Financial Officer | 0.08% |
| Atul Pande | Independent Director | 0.05% |
| Michael Geffner | Former Chief Medical Officer | 0.04% |
| Douglas Hughes | Independent Director | 0.03% |
| Jay Stout | Chief Technology Officer | 0.02% |
| Christopher Van Tuyl | Chief Legal Officer | 0.02% |
| Tiago Girao | Chief Financial Officer | 0.02% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-10 | Atul Pande | Independent Director | Derivative Exercise and Sale | -3,000 | $8.43–36.00 |
| 2026-10-27 | Tiago Girao | Chief Financial Officer | Open Market Disposition | -6,606 | $28.50 |
| 2026-10-20 | Jay Stout | Chief Technology Officer | Open Market Disposition | -2,595 | $28.94 |
| 2026-10-06 | Christopher Van Tuyl | Chief Legal Officer | Open Market Disposition | -1,327 | $32.06 |
| 2026-10-06 | Melanie Gloria | Chief Operating Officer | Open Market Disposition | -2,241 | $32.06 |
| 2026-10-06 | Jay Stout | Chief Technology Officer | Open Market Disposition | -3,809 | $32.06 |
| 2026-10-01 | Eric Venker | Chief Executive Officer | Derivative Exercise and Sale | -89,392 | $14.46–34.11 |
| 2026-09-30 | Eric Venker | Chief Executive Officer | Derivative Exercise and Retained | +2,795 | $14.46 |
| 2026-09-22 | Christopher Van Tuyl | Chief Legal Officer | Open Market Disposition | -2,846 | $36.36 |
| 2026-08-27 | Atul Pande | Independent Director | Derivative Exercise and Sale | -1,500 | $8.43–43.27 |
| 2026-08-19 | Melanie Gloria | Chief Operating Officer | Open Market Disposition | -3,056 | $44.16 |
| 2026-07-23 | Atul Pande | Independent Director | Derivative Exercise and Sale | -1,500 | $8.43–39.80 |
| 2026-07-22 | Tiago Girao | Chief Financial Officer | Open Market Disposition | -6,798 | $38.69 |
| 2026-07-22 | Jay Stout | Chief Technology Officer | Open Market Disposition | -2,857 | $38.69 |
| 2026-07-07 | Christopher Van Tuyl | Chief Legal Officer | Open Market Disposition | -1,206 | $39.53–39.99 |
| 2026-07-07 | Melanie Gloria | Chief Operating Officer | Open Market Disposition | -2,036 | $39.53–39.99 |
| 2026-07-07 | Jay Stout | Chief Technology Officer | Open Market Disposition | -3,487 | $39.53–39.99 |
| 2026-07-01 | Eric Venker | Chief Executive Officer | Derivative Exercise and Sale | -89,721 | $14.46–38.48 |
| 2026-06-30 | Eric Venker | Chief Executive Officer | Derivative Exercise and Retained | +2,467 | $14.46 |
| 2026-06-25 | Atul Pande | Independent Director | Derivative Exercise and Sale | -1,500 | $8.43–38.01 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Immunovant discussion 0 comments